OxSonics Signs Evaluation Agreement with Large Pharma Company
Nicholas Adams Joins OxSonics as Chief Business Officer
OxSonics Raises £10.5m in Oversubscribed Series B2 Equity Financing
Oxford, UK – 9th December 2020 – OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced that it has entered into an evaluation agreement with a Large Pharma company to explore the potential use of the Company’s proprietary SonoTran® Platform with a novel anti-cancer therapeutic agent.
“We are very excited to be collaborating with this Large Pharma company, a company developing highly innovative therapies for the treatment of cancer,” said Colin Story, OxSonics Therapeutics Co-founder and CEO. “This collaboration follows our strategy of applying the SonoTran Platform across in-house and partnered programs to maximise its combination with multiple drug classes and use in multiple patient groups.”
The collaboration will focus on the combination of the Company’s SonoTran Platform with a novel undisclosed clinical-stage anti-cancer therapeutic being developed by the Large Pharma company. Financial terms of the agreement are not being disclosed.
The agreement is in line with OxSonics Therapeutics’ strategy of collaborating with pharmaceutical and biotechnology companies to significantly enhance the tumour penetration of anti-cancer therapies such as antibodies, antibody drug conjugates (ADCs), oncolytic viruses, and small molecules across a broad range of solid tumour cancer types. The SonoTran Platform can be utilised to solve a variety of unmet challenges not only related to efficacy, but also dose limiting toxicity and the enablement of optimal administration routes. Crucially, SonoTran avoids delays and development costs associated with drug reformulation making it an attractive proposition for the de-risking of clinical programs.
– ENDS –
About OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.
The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.
The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.
For more information please visit: www.oxsonics.com.
Nicholas Adams Joins OxSonics as Chief Business Officer
Oxford, UK – 5th August 2020 – OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced that Mr. Nicholas Adams has joined the company as Chief Business Officer.
Nicholas brings over 30years experience in the pharmaceutical and biotech industries and for the past 16 years has led entire Business Development functions at, and been on the Executive Teams of, Antisoma, Clavis Pharma, Redx Pharma and most recently ReNeuron. Over this time Nicholas has led or been instrumental in over 25 global deals (including in-and out-licensing, divestments, spin-outs, royalty buy-out and M&A) where the out-licensing and divestment deals generated over US$240m.
Nicholas will lead the Business Development function and drive clinician engagement for the company.
Colin Story, CEO, commented: “I’m delighted to welcome Nick to the executive team as Chief Business Officer. Nick not only brings a wealth of experience both from his earlier career in oncology clinical development but also an enviable track record of consistent high value deal making across many years in commercial roles. As we transition to a clinical stage company Nick is ideally placed to drive our partnering programmes and clinician engagement activities forward.”
Nicholas Adams, CBO, commented: “I’ve followed OxSonics impressive progress over the past 18 months and I’m delighted to join as it transitions into being a clinical stage company. I look forward to forming partnerships with Pharma companies and building a network of clinical collaborators.”
– ENDS –
About OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.
The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.
The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.
OxSonics is based in Oxford in the UK.
For more information please visit: www.oxsonics.com.
OxSonics® Raises £10.5m in Oversubscribed Series B2 Equity Financing
Oxford, UK – 1st July 2020 – OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced that a £10.5m Series B2 financing round had been closed. The financing round consisting of existing and new investors was oversubscribed.
The capital will be used to take OxSonics’ innovative SonoTran® platform technology into first-in-human clinical trials and to fund other strategic development areas.
Colin Story, CEO, commented: “We’d like to take this opportunity to thank our existing and new investors for their participation in this financing round. In transitioning to a clinical stage company, OxSonics will see its ground-breaking SonoTran technology deployed in the oncology ward setting for those patients with ‘tough to treat’ solid tumours. The whole team at OxSonics have worked very hard to develop this world-leading technology and are equally excited to see it progress to clinical use.”
– ENDS –
About OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.
The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.
The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.
OxSonics is based in Oxford in the UK.
For more information please visit: www.oxsonics.com.